AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03667794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: measurement of conventional lung function parameters
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indacaterol
Description: Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indacaterol matching placebo
Description: Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
Study NCT02474459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad-Based Clinical Support Care
Description: Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
Study NCT02474459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Care
Description: Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
Study NCT00413452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg once weekly
Study NCT02172924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Decidual stromal cell therapy
Description: Intervention given within 7 days after corticosteroids.
Study NCT02172924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Late Decidual stromal cell therapy
Description: Intervention given after 7 days after corticosteroids.
Study NCT02338141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable colposcopy (Cerviscope)
Description: HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
Study NCT02338141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colposcopy (Wallach Zoomscope)
Description: HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
Study NCT02257385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
Study NCT02123810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPR
Description: Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
Study NCT01284946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exjade
Description: Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
Study NCT02550106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMALIZUMAB
Description: sub cutaneous injections of 300 mg every 4 weeks until Week 8.
Study NCT02256852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN SSI
Description: QBKPN SSI is administered subcutaneously for 12 weeks
Study NCT00811369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant + ZACTIMA
Description: ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
Study NCT00811369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant + Placebo
Description: ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
Study NCT01977794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol/Amlodipine (Bisoprolol failed group)
Description: Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
Study NCT01977794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol/Amlodipine (Amlodipine failed group)
Description: Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
Study NCT00766337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus in combination with ranibizumab
Description: Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Study NCT00766337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus in combination with ranibizumab
Description: Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Study NCT00766337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with ranibizumab
Description: Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
Study NCT01101503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial group
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c >=5.5%and \<=6.0%,fasting blood glucose >=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose >= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target >=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Study NCT01101503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional multifactorial therapy group
Description: Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c >6.5%and \<=7.0%,fasting blood glucose >6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose > 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C > 1.9 mmol/L and \< =2.5 mmol/L, triglyceride > 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target >130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin.
Study NCT03346278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
Study NCT01101984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diquafosol ophthalmic solution
Description: DE-089 topical ocular application, 6 times daily for 4 weeks.
Study NCT01101984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate ophthalmic solution.
Description: 0.1% HA topical ocular application, 6 times daily for 4 weeks.
Study NCT01101984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% sodium hyaluronate ophthalmic solution.
Description: 0.1% HA topical ocular application, 6 times daily for 4 weeks.
Study NCT01270412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (Preparation Rich in Growth Factors)
Description: intra articular injection 6ml
Study NCT01270412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (Preparation Rich in Growth Factors)
Description: intra articular injection 6ml
Study NCT01270412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: Intra articular injections: 20 mg / 2 ml
Study NCT00838396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 CR
Study NCT00838396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for XP19986 CR
Study NCT00215332 — intervention group
Intervention type: DEVICE
Intervention: CHARITE
Description: Lumbar Total Disc Replacement
Study NCT02417831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin capsules
Study NCT02417831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin HCl
Study NCT00501670 — intervention group
Intervention type: PROCEDURE
Intervention: Herpes zoster sampling procedure for VZV PCR
Description: Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
Study NCT00501670 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
Study NCT04072497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One shot of the zoster vaccine
Description: One shot of the zoster vaccine (with live virus >=4.3 LgPFU per dose)
Study NCT04072497 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: One shot of the varicella vaccine
Description: One shot of the varicella vaccine (with live virus >=3.3 LgPFU per dose)
Study NCT04072497 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one shot of placebo
Description: one shot of placebo with no live virus
Study NCT01246700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Attention Focused Exercise (SAFEx)
Description: Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks.
Study NCT01246700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Attention Focused Exercise (SAFEx)
Description: Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks.
Study NCT03304743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dental panoramic radiograph
Description: If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints.
Study NCT02299830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: use cryotherapy to delete soft neoplasm tissue in the airway
Study NCT02299830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation
Description: use argon plasma coagulation to delete hard neoplasm tissue in the airway
Study NCT02299830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent placement
Description: use stent placement to open the airway compressed by out neoplasm
Study NCT02299830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deletion tumor tissue by snare
Description: use snare to delete polypoid neoplasm tissue in the airway
Study NCT03364868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
Study NCT03364868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
Study NCT01304316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Study NCT00552721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy with strength training
Description: 12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
Study NCT00552721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy without strength training
Description: 12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
Study NCT00621985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
Study NCT00621985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
Study NCT03379168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfragmented Adipose Tissue (Lipogems)
Description: Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
Study NCT03379168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Cortisone is a standard of care injection to reduce joint inflammation.
Study NCT03017612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
Study NCT03214029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac troponin testing
Description: Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
Study NCT01333891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
Study NCT01333891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium-Nitroprusside
Description: Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
Study NCT01333891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Cup
Description: experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
Study NCT01333891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements
Study NCT01333891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1060nm Optical coherence tomography
Description: Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
Study NCT02898753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-1221
Description: VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
Study NCT02898753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAL-1221
Description: VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
Study NCT02898753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RhGAA
Description: Active comparator
Study NCT01782235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study NCT01782235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05269979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention of hip fractures
Description: Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
Study NCT03756506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Microbicidal Liquid Polymer
Description: The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
Study NCT02076373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human Erythropoietin
Description: i.v. administration
Study NCT02076373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v. administration
Study NCT03667794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: measurement of central and peripheral airway resistance
Study NCT03667794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: measurement of ventilation heterogeneity
Study NCT01253967 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of stool samples
Description: Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
Study NCT01253967 — intervention group
Intervention type: OTHER
Intervention: Health economics questionnaire
Description: For a subset of subjects, additional economic data will be gathered by completing a questionnaire